{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:42:32Z","timestamp":1793306552441,"version":"4.5.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP23K15773"],"award-info":[{"award-number":["JP23K15773"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. Hence, this study aimed to assess the oncological outcomes of patients with SUC treated with EV for metastatic disease. We retrospectively evaluated consecutive patients with advanced lower and upper urinary tract cancer who received EV after platinum-based chemotherapy and immune checkpoint blockade therapy at six institutions. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between patients with pure urothelial carcinoma (PUC) and those with SUC. We identified 44 and 18 patients with PUC and SUC, respectively. Squamous differentiation was the most common subtype element, followed by glandular differentiation and sarcomatoid subtype. Although patients with SUC had a comparable ORR to those with PUC, the duration of response for SUC was short. Patients with SUC had poorer PFS than those with PUC; however, no significant difference was observed in OS. Multivariate analysis revealed that SUC was significantly associated with shorter PFS. Although the response of metastatic SUC to EV was similar to that of PUC, SUC showed faster progression than PUC.<\/jats:p>","DOI":"10.3390\/curroncol31020064","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T08:28:16Z","timestamp":1707294496000},"page":"862-871","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"31","author":[{"given":"Akinori","family":"Minato","sequence":"first","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Furubayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Tomoda","sequence":"additional","affiliation":[{"name":"Department of Urology, Oita Prefectural Hospital, Oita 870-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Masaoka","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoohyun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 880-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Kiyoshima","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka 815-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Negishi","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kuroiwa","sequence":"additional","affiliation":[{"name":"Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 880-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihito","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikko","family":"Tomisaki","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: Early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.23736\/S0393-2249.18.03175-2","article-title":"The pathologist\u2019s role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection","volume":"70","author":"Mantica","year":"2018","journal-title":"Minerva Urol. Nefrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: Prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_9","unstructured":"Minato, A., Murooka, K., Okumura, Y., Takaba, T., Higashijima, K., Nagata, Y., Tomisaki, I., Harada, K., and Fujimoto, N. Efficacy of platinum-based chemotherapy in patients with metastatic urothelial carcinoma with variant histology, In Vivo, in press."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/JU.0000000000001305","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori","year":"2020","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","article-title":"Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis","volume":"203","author":"Mori","year":"2020","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hsieh, M.C., Sung, M.T., Chiang, P.H., Huang, C.H., Tang, Y., and Su, Y.L. (2015). The prognostic impact of histopathological variants in patients with advanced urothelial carcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129268"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"499.e1","DOI":"10.1016\/j.clgc.2022.05.001","article-title":"Efficacy of pembrolizumab in patients with variant urothelial carcinoma: A multicenter retrospective study","volume":"20","author":"Minato","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline, version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100325","DOI":"10.1016\/j.ctarc.2021.100325","article-title":"Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience","volume":"27","author":"Swami","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: Survival and safety in a European multicenter real-world patient cohort","volume":"53","author":"Biernath","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Ralser","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of nectin-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rodler, S., Eismann, L., Schlenker, B., Casuscelli, J., Brinkmann, I., Sendelhofert, A., Waidelich, R., Buchner, A., Stief, C., and Schulz, G.B. (2022). Expression of nectin-4 in variant histologies of bladder cancer and its prognostic value-need for biomarker testing in high-risk patients?. Cancers, 14.","DOI":"10.3390\/cancers14184411"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: A rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"436.e1","DOI":"10.1016\/j.urolonc.2021.01.031","article-title":"Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma","volume":"39","author":"Paciotti","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: A propensity score-weighted analysis from the national cancer data base","volume":"34","author":"Seisen","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:19Z","timestamp":1760104459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["curroncol31020064"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31020064","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]}}}